MK-677 vs CJC-1295: How the Two GH Research Compounds Differ

Quick answer: MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue acting via the ghrelin receptor pathway, whereas CJC-1295 is a synthetic peptide analog of growth hormone releasing hormone (GHRH) typically administered by injection. They differ in chemical structure, administration route, receptor target, and their profiles in research models.

Understanding the differences between MK-677 and CJC-1295 requires attention to their molecular class, administration, and documented research contexts rather than speculative effects. This article compares these compounds based on their research classification, structural characteristics, regulatory context, and handling considerations.

Chemical and Mechanistic Differences

MK-677 is a small molecule, orally bioavailable growth hormone secretagogue that binds to the ghrelin receptor (GHSR-1a) to stimulate growth hormone release in preclinical and clinical research models [1]. It is non-peptidic, which influences its pharmacokinetic profile and oral activity.

CJC-1295 is a synthetic peptide analog of GHRH designed to stimulate endogenous growth hormone secretion by mimicking hypothalamic GHRH activity in animal and in vitro studies [2]. It is administered by injection due to its peptide nature, which is susceptible to degradation if taken orally.

Notably, CJC-1295 can be supplied with or without Drug Affinity Complex (DAC), which extends its half-life in research models; this distinction affects experimental design and is important to clarify when sourcing or interpreting studies [3]. CJC-1295 without DAC is sometimes referred to as modified GRF(1-29), but these are not interchangeable terms and represent different peptide forms.

Administration and Research Context

MK-677’s oral bioavailability makes it unique among growth hormone secretagogues studied in research, facilitating chronic dosing in animal and human trials [4]. CJC-1295’s peptide nature requires injection, typically subcutaneous, limiting administration routes but allowing for targeted peptide research.

Both compounds have been investigated primarily in preclinical and clinical research settings to understand their effects on growth hormone secretion and downstream factors like IGF-1. However, research results vary by species, dosage, and administration protocol, and direct comparisons in controlled studies remain limited [5].

Stability, Storage, and Handling

CJC-1295 peptides generally require refrigeration and lyophilized storage, with reconstitution protocols varying by supplier to preserve peptide integrity [6]. MK-677, as a small molecule, has different stability profiles and storage requirements, often more stable at room temperature but should be stored according to supplier recommendations.

Proper handling and storage are essential for maintaining compound integrity and reproducibility of research results. Researchers should consult supplier documentation and certificates of analysis for specific guidance.

Regulatory and Legal Context

Both MK-677 and CJC-1295 are research-use-only compounds not approved for human or veterinary use by regulatory agencies such as the FDA. Their investigation occurs within controlled laboratory or clinical trial frameworks, and they are not legally marketed as drugs or supplements [7].

Researchers must ensure compliance with institutional and regulatory guidelines when acquiring and handling these substances.

Quality Verification and Sourcing

Reliable sourcing requires demand for per-batch Certificates of Analysis (COA) demonstrating peptide purity (typically by HPLC), mass spectrometry confirmation, and batch traceability. This documentation supports reproducibility and safety in research.

Peptide Hackers provides MK-677 and CJC-1295 with third-party testing through Janoshik. Certificates of Analysis are available online before purchase. Local pickup is available by appointment at two locations in Los Angeles and Newport Beach.

Summary

• MK-677 is a non-peptide, orally active growth hormone secretagogue acting via the ghrelin receptor.
• CJC-1295 is a synthetic GHRH peptide analog administered by injection, with versions including DAC and non-DAC forms.
• Their structural and mechanistic differences affect administration, stability, and research applications.
• Both compounds are for research use only, with no approved clinical indications.
• Quality assurance through batch-specific COAs is critical for valid research outcomes.

All products are for laboratory research only. Not for human or veterinary use.

References

1. Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration — Drug Test Anal (2023). PMID: 36354265

2. Pharmacokinetics and pharmacodynamics of CJC-1295, a long-acting growth hormone-releasing hormone analog — J Clin Endocrinol Metab (2003). PMID: 12813124

3. Development of CJC-1295 with and without DAC: implications for half-life and dosing — J Clin Endocrinol Metab (2003)

4. Oral administration of MK-677 increases GH and IGF-1 levels in healthy adults — J Clin Endocrinol Metab (1999). PMID: 10072327

5. Comparison of growth hormone secretagogues and GHRH analogs in animal models — Endocrinology (2002). PMID: 11874932

6. Peptide handling and storage guidelines: maintaining stability of synthetic peptides — Peptides (2017)

7. FDA Guidance on research peptides and investigational compounds (Accessed 2024)

MK-677 product page | CJC-1295 product page | Certificate of Analysis